NCT06577194View on ClinicalTrials.gov

A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 5, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

October 31, 2028

Conditions
Rectal CancerAdvanced Solid Tumor
Interventions
DRUG

Sintilimab + IL-2 Combined with CAPOX

Sintilimab + IL-2 Combined with Capox

RADIATION

Short-course radiotherapy

Short-course radiotherapy+IL-2

Trial Locations (1)

210000

RECRUITING

Jiangsu Province Hospital, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER